Enzyme therapy for Fabry's disease: registered for success?

The Lancet

Volumn 374, Issue 9706, 2009, Pages 1950-1951

  Knebelmann, Bertrand ^a   Kurschat, Christine ^b   Thadhani, Ravi ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; GLYCOSPHINGOLIPID; NEUTRALIZING ANTIBODY;

ACROPARESTHESIA; ADULTHOOD; ARTICLE; CELL TYPE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CORONARY FLOW RESERVE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEMANGIOKERATOMA; HEMIZYGOSITY; HETEROZYGOTE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIPID STORAGE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; ONSET AGE; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SAMPLE SIZE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; THERAPY EFFECT; VALVULAR HEART DISEASE; X CHROMOSOME LINKED DISORDER;

EID: 71649085292     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61838-9     Document Type: Note

References (14)

1. Zarate Y.A., and Hopkin R.J. Fabry's disease. Lancet 372 (2008) 1427-1435
2. Pastores G.M., and Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 358 (2001) 601-603
3. Linhart A., Lubanda J.-C., Palecek T., et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24 suppl 2 (2001) 75-83
4. Schiffmann R., Kopp J.B., Austin III H.A., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
5. Eng C.M., Guffon N., Wilcox W.R., et al., for the International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
6. West M., Nicholls K., Mehta A., et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20 (2009) 1132-1139
7. Mehta A., Beck M., Elliott P., et al., on behalf of the Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet (2009) 10.1016/S0140-6736(09)61493-8 published online Dec 2.
8. Schiffmann R., Warnock D.G., Banikazemi M., et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24 (2009) 2102-2111
9. Germain D.P., Waldek S., Banikazemi M., et al. Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease. J Am Soc Nephrol 18 (2007) 1547-1557
10. Thadhani R., Wolf M., West M.L., et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 61 (2002) 249-255
11. Ortiz A., Oliveira J.P., Wanner C., Brenner B.M., Waldek S., and Warnock D.G. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 4 (2008) 327-336
12. Tahir H., Jackson L.L., and Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β. J Am Soc Nephrol 18 (2007) 2609-2617
13. Warnock D.G. Enzyme replacement therapy and Fabry kidney disease: quo vadis?. J Am Soc Nephrol 18 (2007) 1368-1370
14. Schiffmann R., Askari H., Timmons M., et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18 (2007) 1576-1583